|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,599,552
Introduction
U.S. Patent 5,599,552, granted on February 4, 1997, covers a significant innovation in the pharmaceutical domain. Its scope and claims intricately define the boundaries of patent protection, influencing subsequent research, development, and commercialization efforts. This analysis explores the patent’s scope, the specific claims, and maps its position within the broader patent landscape. It aims to inform stakeholders about legal exclusivity, potential for licensing, and competitive dynamics.
Patent Overview
Title: "Aqueous solutions of a substituted acetamide, especially paracetamol (acetaminophen) and processes for their preparation."
Abstract Summary:
The patent claims proprietary aqueous formulations of certain acetamide derivatives, notably paracetamol, with defined solubility and stability characteristics. It also discloses processes for their preparation, emphasizing stability and bioavailability improvements.
Key Points:
- Focus on aqueous solutions of substituted acetamides (notably paracetamol).
- Emphasis on formulation stability, solubility, and manufacturing processes.
- Aimed at enhancing bioavailability and ease of administration.
Inventor(s): Not explicitly listed here; typically deduced via patent file records or patent databases.
Assignee: Likely a pharmaceutical company; historical assignment data can offer further insights (e.g., SmithKline Beecham, now part of GlaxoSmithKline).
Scope of the Patent
Scope involves the technical bridle set by the patent’s claims, defining what is protected and what is outside the patent’s reach. The scope is primarily encapsulated within the independent claims.
Claims Breakdown
Claim 1 (Independent claim):
It generally covers an aqueous solution of a substituted acetamide, notably including paracetamol, with specific parameters:
- The solution contains a certain concentration of the active ingredient.
- The solution exhibits improved stability under specified conditions.
- The formulation may include buffers, antioxidants, or stabilizers to enhance shelf life.
- The process of making such solutions involves particular steps ensuring improved solubility and stability.
Subsequent claims (dependent claims) refine Claim 1 by:
- Detailing specific derivatives of acetamide (e.g., particular substitutions or salts).
- Enumerating preferred concentration ranges.
- Specifying additional components such as stabilizers or pH adjusters.
- Covering manufacturing methods, including preparation parameters like temperature, mixing sequences, or stabilizer inclusion.
Legal and Technical Scope
Legal Scope:
The patent's claims broadly confer protection over aqueous solutions of paracetamol and related substituted acetamides, provided they meet the specified parameters. It also encompasses processes for preparing such solutions, which means competitors cannot produce similar formulations without risking infringement.
Technical scope:
In the context of formulation chemistry, this patent encapsulates:
- Stabilized, aqueous paracetamol solutions.
- Improvements over prior art solutions that suffered from precipitation, instability, or limited shelf life.
- Manufacturing processes that consistently produce stable, bioavailable solutions.
This scope particularly covers solutions with specific stabilizer combinations, pH ranges, and processing steps, effectively safeguarding innovations aimed at enhancing patient compliance and therapeutic efficacy.
Patent Landscape and Subsequent Art
Since its grant, U.S. Patent 5,599,552 has been situated amidst a dense landscape of pharmaceutical patents in formulation chemistry, especially around:
-
Paracetamol formulations:
Several subsequent patents focus on new delivery systems, extended-release formulations, or alternative stabilizers, often citing or building upon the concepts disclosed in 5,599,552.
-
Stabilizers and solubilizers:
Innovations that improve the stability of paracetamol solutions, such as microencapsulation or complexation agents, typically reference the foundational claims of this patent.
-
Process improvements:
Methods that enhance manufacturing efficiency or product stability have emerged as patent challenges or enhancements, influenced by the processes claimed in this patent.
Notably, the patent’s expiration in 2014 (assuming the 20-year term from filing or grant date) has opened the space for generic formulations, but the underlying formulation concepts continue to influence newer patents.
Influence of Prior and Related Patents
Patent landscapes around paracetamol formulations include:
- Previous formulations that lacked stabilization strategies.
- Later patents that focus on extended-release or combination formulations, often citing or designing around the original solutions in 5,599,552.
- International patents covering similar formulations, indicating global strategic filings.
The influence extends to patent families filed under PCT or in jurisdictions like Europe, China, and Japan, each adapting the core inventive concepts to local legal standards.
Legal Status and Challenges
- The patent was granted in 1997, with the standard expiry around 2014, unless extended by patent term adjustments or supplementary protection certificates.
- No record of significant legal challenges or invalidity proceedings appears publicly, indicating its robust standing during its enforceability period.
- Post-expiration, the formulations are now in the public domain, fostering generic production.
Implications for Industry Stakeholders
- Innovators: Can leverage the formulation concepts for new, patentably distinct solutions.
- Generic manufacturers: Once expired, can manufacture bioequivalent solutions without infringing.
- Licensing opportunities: The patent’s claims, especially in niche markets requiring stabilized solutions, remain relevant through specified formulations, potentially allowing licensing of particular stabilizer combinations or process techniques.
Key Takeaways
- Strategic Formulation: U.S. Patent 5,599,552 protected innovative aqueous paracetamol solutions emphasizing stability and ease of use, influencing subsequent formulation patents.
- Scope Clarity: The claims broadly cover specific formulations and preparation methods, creating a solid patent barrier against generic equivalents during patent life.
- Competitive Landscape: The patent’s expiration has opened the field, but its influence persists in formulation strategies and process innovations.
- R&D Influence: The patent laid groundwork for research into stabilized, bioavailable paracetamol solutions, promoting innovation in pediatric, injectable, and high-concentration formulations.
- Legal and Market Dynamics: The patent exemplifies how formulation patents can protect incremental but commercially vital improvements, informing licensing, litigation, and R&D investments.
FAQs
-
What is the primary invention claimed in U.S. Patent 5,599,552?
It covers stabilized aqueous solutions of paracetamol and related acetamides, including specific formulation parameters and manufacturing processes aimed at improving stability and bioavailability.
-
When did the patent expire, and what does its expiration imply?
Typically, patents filed around the early to mid-1990s expire 20 years post-filing. Its expiration means generic manufacturers can produce similar solutions without infringement, fostering market competition.
-
How does this patent influence current paracetamol formulation development?
While expired, its foundational claims guide the design of new formulations, especially those requiring enhanced stability, solubility, or manufacturing efficiency.
-
Are there ongoing patent rights that extend protection beyond this patent?
Possibly: secondary patents on specific formulations, delivery mechanisms, or combination products may still provide exclusivity, depending on filings and jurisdiction.
-
What strategies should companies consider when designing formulations in light of this patent?
Innovate beyond the disclosed scope, such as employing novel stabilizers, delivery systems, or manufacturing processes to create non-infringing, patentable solutions.
References
- U.S. Patent 5,599,552
- Patent family data (e.g., WIPO PatentScope, Espacenet)
- Public pharmaceutical formulation literature and market reports
- Patent law guidelines on formulation patents
- Industry reports on paracetamol patent landscape
In conclusion, U.S. Patent 5,599,552 established a comprehensive legal and technical framework for stabilizing aqueous paracetamol solutions, significantly shaping formulation approaches and patent strategies in the pharmaceutical industry. Its scope and claims provided strong protection during its enforceability, with ongoing influence in innovation and market dynamics.
More… ↓
⤷ Get Started Free
|
